|Articles|June 26, 2015

GSK to Sell Legacy Vaccines to Pfizer

June 26, 2015.

GlaxoSmithKline has announced that it will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals. The €115m sale is subject to final European Commission approval, other regulatory approvals, and other customary closing conditions and is expected to close before the end of the year.

Source: GSK

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

GSK to Sell Legacy Vaccines to Pfizer

Related Content

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Additive Manufacturing's Application in Pharma and Biotech

Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor

The ROI of Smarter Trials: Q&A with Raj Indupuri

Trending on PharmExec

The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market

Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion

Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last

Catalent Announces Expanded Partnership with Nanoscope Therapeutics

Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization